Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Z. Orlowski, Shibao Feng, Karim S. Iskander, Meletios A. Dimopoulos

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib–dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.

Original languageEnglish
Pages (from-to)1364-1374
Number of pages11
JournalLeukemia and Lymphoma
Volume59
Issue number6
DOIs
Publication statusPublished - 2018

Keywords

  • bortezomib
  • carfilzomib
  • intravenous
  • Multiple myeloma
  • progression-free survival
  • subcutaneous

Cite this

Goldschmidt, Hartmut ; Moreau, Philippe ; Ludwig, Heinz ; Niesvizky, Ruben ; Chng, Wee Joo ; Joshua, Douglas ; Weisel, Katja ; Spencer, Andrew ; Orlowski, Robert Z. ; Feng, Shibao ; Iskander, Karim S. ; Dimopoulos, Meletios A. / Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma : secondary analysis of the phase 3 ENDEAVOR study. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 6. pp. 1364-1374.
@article{a342b195709647989194d8b660ccbcc1,
title = "Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study",
abstract = "This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib–dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.",
keywords = "bortezomib, carfilzomib, intravenous, Multiple myeloma, progression-free survival, subcutaneous",
author = "Hartmut Goldschmidt and Philippe Moreau and Heinz Ludwig and Ruben Niesvizky and Chng, {Wee Joo} and Douglas Joshua and Katja Weisel and Andrew Spencer and Orlowski, {Robert Z.} and Shibao Feng and Iskander, {Karim S.} and Dimopoulos, {Meletios A.}",
year = "2018",
doi = "10.1080/10428194.2017.1376743",
language = "English",
volume = "59",
pages = "1364--1374",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",
number = "6",

}

Goldschmidt, H, Moreau, P, Ludwig, H, Niesvizky, R, Chng, WJ, Joshua, D, Weisel, K, Spencer, A, Orlowski, RZ, Feng, S, Iskander, KS & Dimopoulos, MA 2018, 'Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study' Leukemia and Lymphoma, vol. 59, no. 6, pp. 1364-1374. https://doi.org/10.1080/10428194.2017.1376743

Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma : secondary analysis of the phase 3 ENDEAVOR study. / Goldschmidt, Hartmut; Moreau, Philippe; Ludwig, Heinz; Niesvizky, Ruben; Chng, Wee Joo; Joshua, Douglas; Weisel, Katja; Spencer, Andrew; Orlowski, Robert Z.; Feng, Shibao; Iskander, Karim S.; Dimopoulos, Meletios A.

In: Leukemia and Lymphoma, Vol. 59, No. 6, 2018, p. 1364-1374.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma

T2 - secondary analysis of the phase 3 ENDEAVOR study

AU - Goldschmidt, Hartmut

AU - Moreau, Philippe

AU - Ludwig, Heinz

AU - Niesvizky, Ruben

AU - Chng, Wee Joo

AU - Joshua, Douglas

AU - Weisel, Katja

AU - Spencer, Andrew

AU - Orlowski, Robert Z.

AU - Feng, Shibao

AU - Iskander, Karim S.

AU - Dimopoulos, Meletios A.

PY - 2018

Y1 - 2018

N2 - This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib–dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.

AB - This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib–dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.

KW - bortezomib

KW - carfilzomib

KW - intravenous

KW - Multiple myeloma

KW - progression-free survival

KW - subcutaneous

UR - http://www.scopus.com/inward/record.url?scp=85029896256&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1376743

DO - 10.1080/10428194.2017.1376743

M3 - Article

VL - 59

SP - 1364

EP - 1374

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -